On Nov 12, major Wall Street analysts update their ratings for $Evolent Health (EVH.US)$, with price targets ranging from $19 to $36.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $39 to $19.
UBS analyst Kevin Caliendo maintains with a buy rating, and adjusts the target price from $46 to $27.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $63 to $36.
RBC Capital analyst Sean Dodge maintains with a buy rating, and adjusts the target price from $42 to $20.
Truist Financial analyst Jailendra Singh maintains with a buy rating, and adjusts the target price from $33 to $24.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
The third-quarter performance miss for Evolent Health, though disheartening, is not an outlier in the current risk climate, and the core business model continues to hold strong.
Evolent Health's Q3 EBITDA was notably below consensus, primarily due to a substantial rise in Oncology-related costs, both retrospectively and within the quarter. Nonetheless, Evolent reported signing new run-rate business amounting to $200M in Q3, which underscores the increasing demand for specialty care management.
Evolent Health's third-quarter outcomes were characterized as less than satisfactory, leading to a reassessment of its performance trajectory. Previously, it appeared that the company was poised to mitigate elevated expenses through contractual rate enhancements. However, the market's response indicates skepticism regarding Evolent's ability to achieve the anticipated $300M EBITDA target. Despite these sentiments, the prevailing belief among analysts is that the company's margins will stabilize as pricing adjustments materialize over time.
Here are the latest investment ratings and price targets for $Evolent Health (EVH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月12日，多家华尔街大行更新了$Evolent Health (EVH.US)$的评级，目标价介于19美元至36美元。
巴克莱银行分析师Stephanie Davis维持买入评级，并将目标价从39美元下调至19美元。
瑞士银行分析师Kevin Caliendo维持买入评级，并将目标价从46美元下调至27美元。
TD Cowen分析师Charles Rhyee维持买入评级，并将目标价从63美元下调至36美元。
加皇资本市场分析师Sean Dodge维持买入评级，并将目标价从42美元下调至20美元。
储亿银行分析师Jailendra Singh维持买入评级，并将目标价从33美元下调至24美元。
此外，综合报道，$Evolent Health (EVH.US)$近期主要分析师观点如下：
Evolent Health第三季度业绩下滑，尽管令人沮丧，但在当前风险氛围中并不是一个孤立现象，核心业务模式仍然持续稳固。
Evolent Health的Q3 EBITDA明显低于共识，主要是由于肿瘤相关成本大幅上升，无论是回顾性地还是在本季内。尽管如此，在第三季度Evolent报告称签订了总额为$20000万的新业务金额，这凸显了对专科护理管理需求的增长。
Evolent Health第三季度的业绩被描述为令人不甚满意，导致其绩效轨迹重新评估。此前，看起来该公司似乎准备通过合同费率提高来缓解高昂成本。然而，市场的反应显示出对Evolent实现预期的$30000万 EBITDA目标的怀疑。尽管有这些观点，分析师普遍认为，随着定价调整逐渐形成，公司的利润率将会稳定。
以下为今日5位分析师对$Evolent Health (EVH.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
